U.S. Sen. Claire McCaskill
WASHINGTON, D.C. (Oct. 26, 2015) — U.S. Sen. Claire McCaskill today responded to a conference call Valeant held with its investors, as well as to a recent letter the company sent her after she had demanded answers regarding Valeant’s dramatic increase in the price of some of its medications. Valeant failed to provide a complete response to McCaskill’s questions.
Responding to this morning’s call with investors, McCaskill, a former auditor, said: “The only thing that this morning’s investor call made clear is that Valeant’s questionable business practices extend well beyond price gouging. While I look forward to hearing more about the company’s ad hoc committee, the fact that all four members of the committee are on the board of makes it hard for me to believe that their inquiry will be independent or unbiased.”
McCaskill also responded to a recent letter Valeant provided to her office, which she described as “deeply disappointing.” A copy of McCaskill’s response to Valeant is available online HERE.
In a Senate hearing in July, McCaskill questioned former Valeant CFO Howard Schiller regarding Valeant’s February 2015 move to increase the price per vial of Isuprel, a medication used to treat cardiac arrest, from $215 to $1,346. That same month, Valeant also increased the price per vial of the drug Nitropress from $257.80 to $805.61.
Visit mccaskill.senate.gov/accountability to learn more about McCaskill’s fight for stronger accountability in Washington.
Click here to follow the Pulaski County Daily News on Twitter
Click here to follow the Pulaski County Daily News on Facebook